Coherus Oncology (CHRS) Asset Writedowns and Impairment (2015 - 2025)

Coherus Oncology has reported Asset Writedowns and Impairment for 9 years, with the latest figure at $12.5 million in Q4 2025.

• Quarterly Asset Writedowns and Impairment rose 68.96% year-over-year to $12.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.3 million (up 43.71% YoY) and the FY2025 annual result came in at $14.1 million, changed 0.3% from the prior year.
• Asset Writedowns and Impairment climbed to $12.5 million in Q4 2025 per CHRS's latest filing, from $500000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $48.2 million in Q4 2023 and troughed at -$347000.0 in Q2 2023.
• A 5-year average of $9.6 million and a median of $3.2 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment sank 94.33% in 2023, then soared 109.81% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at -$59000.0 in 2021, then surged by 44167.8% to $26.0 million in 2022, then soared by 85.48% to $48.2 million in 2023, then plunged by 84.72% to $7.4 million in 2024, then surged by 68.96% to $12.5 million in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $12.5 million, $500000.0, and $7.4 million for Q4 2025, Q3 2025, and Q4 2024 respectively.